Waters Corporation (NYSE: WAT) exhibited a notable after-market surge of 6.76% in its stock value on Thursday, reaching a trading price of $314.12. This ascent followed a prior decline of 3.27%, closing at $294.23. The positive momentum emerged after the company announced release date of its financial results.
Waters Corporation (WAT) announced that it will be holding a live conference call to discuss its first-quarter 2024 financial results. The event is scheduled to begin at 8:00 a.m. Eastern Time on Tuesday, May 7, 2024. A live webcast of the presentation is available to interested parties on the company's Investor Relations homepage.
In addition, Waters Corporation recently made headlines with the launch of the Alliance iS Bio HPLC System, which has innovative features designed to address the analytical and operational challenges faced by biopharmaceutical quality control (QC) labs. This state-of-the-art HPLC system combines built-in instrument intelligence capabilities with advanced bio-separation technology.
Its goal is to significantly reduce mistakes by up to 40% and increase operational efficiency for QC analysts working in the biopharmaceutical industry. This reduction in errors translates to significant time savings, previously lost to investigating run failures and out-of-specification outcomes.
The instrument's bio-inert design incorporates Waters MaxPeak HPS Technology into critical internal components, thereby mitigating undesired interactions with metal-absorbing analytes. Additionally, the system is compatible with Waters QuanRecovery Vials and Plates, as well as MaxPeak Premier HPLC Columns featuring eConnect Column Tag Technology.
These synergies facilitate the establishment of robust platform methods, obviating the need for protracted column conditioning and method development processes. Recognizing that human error remains a pervasive challenge impacting productivity and revenue in QC laboratories, Waters Corporation collaborated closely with its clientele to develop the Alliance iS Bio HPLC System.
The objective was to address daily operational challenges and adapt to evolving compliance standards, all while striving to accelerate product release timelines. Each facet of this formidable HPLC platform, from its utilization of bio-inert surface technology at critical sample touchpoints to its intuitive design, underscores Waters Corporation's commitment to simplifying processes and enhancing efficiency for biopharma QC labs.